Lilly bolts on cancer bispecifics with $1.6bn Merus allianceAlways a big player in oncology, Eli Lilly has fallen behind some of its rivals when it comes Share XLilly bolts on cancer bispecifics with $1.6bn Merus alliancehttps://pharmaphorum.com/news/lilly-bolts-on-cancer-bispecifics-with-1-6bn-merus-alliance/
Takeda signs $882m rare disease alliance with Oxford biotech EvoxEvox Therapeutics is the second UK biotech to sign a big deal with a pharma giant this week, Share XTakeda signs $882m rare disease alliance with Oxford biotech Evoxhttps://pharmaphorum.com/news/takeda-signs-882m-rare-disease-alliance-with-oxford-biotech-evox/
Sosei Heptares bags another big partnership, this time with TakedaJapanese biotech Sosei’s buyout of the UK’s Heptares four years ago has rewarded it with a string of Share XSosei Heptares bags another big partnership, this time with Takedahttps://pharmaphorum.com/news/sosei-heptares-bags-another-big-partnership-this-time-with-takeda/
Denmark’s Genmab raises a bumper $500m-plus in Nasdaq IPOGenmab has shattered recent records with its Nasdaq listing, raising $506 million to help it advance multiple antibody Share XDenmark’s Genmab raises a bumper $500m-plus in Nasdaq IPOhttps://pharmaphorum.com/news/denmarks-genmab-raises-a-bumper-500m-plus-in-nasdaq-ipo/
“Partnering with Industry” Session: EuHIC Berlin May 18th 2018Partnering with industry at EuHIC 2018 Share X“Partnering with Industry” Session: EuHIC Berlin May 18th 2018https://pharmaphorum.com/partner-content/partnering-with-industry-session-euhic-berlin-may-18th-2018/